At a Glance
- Company: Boehringer Ingelheim; OSE Immunotherapeutics
- Location: Ingelheim, Germany; Nantes, France
- Headline figures: Phase 2b missed primary endpoint
- Focus area: Immunotherapy for metabolic dysfunction-associated steatohepatitis
- Next steps: OSE explores alternatives; Boehringer refocuses
What happened?
Boehringer Ingelheim terminated its collaboration with OSE Immunotherapeutics on 4 March 2026 following disappointing phase 2b results for their joint MASH candidate. The trial failed to meet its primary endpoint of disease regression without fibrosis worsening, prompting Boehringer to end the partnership.
Why does it matter?
MASH affects 1 in 4 adults globally with few approved therapies; immunotherapies targeting liver inflammation represent high-risk innovation, but repeated phase 2 failures highlight challenges in fibrosis reversal. Termination frees OSE resources while Boehringer prioritises other liver assets.
Who’s behind it?
Boehringer Ingelheim partnered with OSE in 2022 for IL-22 fusion protein; OSE led development with Boehringer funding. French biotech now seeks new collaborators post-setback.
How was it achieved?
Phase 2b tested subcutaneous dosing in 200+ NASH patients; drug showed histological improvements but insufficient statistical separation from placebo on key endpoints after 52 weeks. Safety acceptable but efficacy shortfall triggered contractual termination.
What’s next?
OSE Immunotherapeutics reviews data for alternative indications; Boehringer advances separate MASH assets. No near-term milestones remain from partnership.
What are people saying?
OSE statement: “Exploring strategic options.” Analysts: “Expected given competitive MASH landscape.”